Pharmacy Statutes, Rules & Resources

The Board of Pharmacy, together with the Secretary of State’s Office of Professional Regulation (OPR), provide governance, oversight and enforcement for your profession. This page contains detailed information regarding applicable statutes and rules as well as additional resources.

Statutes & Rules

• Pharmacy Statutes (Vermont Statutes Online)
• 18 V.S.A. § 4215 Regulated Drugs Authorized sales by pharmacists
• 18 V.S.A. § 4215b Regulated Drugs Identification
• 18 V.S.A. § 4289 Vermont Prescription Monitoring System Standards and guidelines for health care providers and dispensers
• Vermont Department of Health Reportable Disease Rule
• Rule Governing the Prescribing of Opioids for Pain
• Alternative Drug or Biological Product Selection (18 V.S.A. § 4605)
• Statutes Governing all Professions
• Administrative Rules
• Interim Rules for Clinical Pharmacy
• Stock Supply and Emergency Administration of Epinephrine Auto-injectors (16 V.S.A. § 1388)
• Board Policy on Licensure of Virtual Drug Manufacturers, Contract Manufacturers, Virtual Manufacturers, Brokers/Intermediaries/Facilitators, and Repackagers/Relabelers
• Licensing Requirements for IV Therapy

Vermont Pharmacist Prescribing Protocols

• Opioid Antagonists
• Self-administered Hormonal Contraceptives
• Covid-19 Vaccine
• Vermont Pharmacist Prescribing Protocol – Tobacco Cessation Products
• Vermont Pharmacist Prescribing Protocol – Emergency Prescribing of Albuterol and Glucagon While Contemporaneously Contacting Emergency Services
• Vermont Pharmacist Prescribing Protocol – Tuberculin Purified Protein Derivative (PPD) Products
• Vermont Pharmacist Prescribing Protocol – Dietary Fluoride Supplements
• Vermont Pharmacist Prescribing Protocol – Epinephrine Auto-Injectors
• Vermont Pharmacist Prescribing Protocol – ACIP Recommended Vaccines
• Vermont Pharmacist Prescribing Protocol – Emergency Contraception
• Vermont Pharmacist Prescribing Protocol - COVID-19 and Influenza age 5 and up

Policies, Protocols, & Guidance Documents

• Pharmacy Technician Certification Requirements email sent to all Pharmacists 12-13-2018
• Internship-Hour Requirements for ACPE-Accredited Programs
• Policy on Permitted CII Prescription Changes after Oral Consultation with Prescriber
  • DEA clarification of Policy on CII Changes, from NABP
• Policy on Legend Device Licensure
• Naloxone Dispensing Protocol
• Current Standing Order for Distribution of Naloxone Prescription for Overdose Prevention
• Vermont Department of Health Naloxone standing order
• New opioid overutilization policies, Effective January 1, 2019. CMS Tip Sheet and Prescribers Guide:
• CMS Tip Sheet
• Prescriber's Guide
• Notice of Required Continuing Education Regarding Controlled Substances

Additional Resources

• National Association of Boards of Pharmacy (NABP)
• NABP Initiative: Mental Health and Well-Being Resources
• Health Insurance Portability and Accountability Act (HIPAA)
• Vermont Department of Health
• Vermont Immunization Registry (888) 688-4667 or email IMR@vermont.gov
• CMS Requirements for Tamper Resistant Prescriptions
• Public Readiness and Emergency Preparedness Act – HHS.gov
• Vermont Pharmacist Association
• Vermont Society of Health System Pharmacists

DEA

• https://www.deadiversion.usdoj.gov/index.html
• Title 21 United States Code (USC) Controlled Substances Act
• Title 21 Code of Federal Regulations, PART 1300-END
• Pharmacist's Manual
• Clarification on Transfer of Unfilled Controlled Substance Prescriptions

FDA

• Code of Federal Regulations, Title 21: Food and Drugs
• Essential FDA resources
• “Purple Book”
• "Orange Book"
• FDA’s Listing of Authorized Generics
• FDA Compounding Laws and Policies
• Drug Supply Chain Security Act (DSCSA)
• Questions and Answers on FDA's Adverse Event Reporting System (FAERS)
• Recalls, Market Withdrawls & Safety Alerts

USP

• https://www.uspnf.com/
• Compounding Standards
• Compendial Notices

National Institute for Occupational Safety and Health (NIOSH)

• List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings

For more answers to commonly asked questions, please visit our General FAQ page.

For more information, please contact us.